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What is the value of the CD classification of leukocyte 
surface antigens? 
Monoclonal antibody technology has led to the 
identification of a large number of leukocyte surface 
structures over the past 15 years. More importantly, 
the antibodies themselves have proven to be powerful 
tools for understanding the function and structure of 
these antigens. Many of these molecules now have 
defined roles in cell signaling, adhesion, and regulation 
of inflammatory processes. An in-depth understanding 
of the function of these molecules is essential to 
defining their importance in inflammatory and auto- 
immune diseases. Hopefully, many of these structures 
will ultimately be suitable targets for new pharmaco- 
logic and biologic therapeutic agents. A large number 
of the leukocyte surface markers have been classified 
in the CD nomenclature. 
With the number of CD antigens now well in 
excess of 100, it becomes increasingly difficult to 
remember the identity of the specific structures in each 
CD cluster. In some ways, the assignment of more 
colorful or descriptive names to individual antigens is 
more compelling. Nevertheless, it is clear that the CD 
classification system is necessary to avert chaos in the 
rapidly expanding field of immunology. It has provided 
a mechanism for determining that investigators work- 
ing with different antibodies in laboratories scattered 
around the world are, in fact, working with reagents to 
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common surface antigens. In many instances this has 
allowed the assignment of as-yet-unclassified mono- 
clonal antibodies to known CD clusters. More impor- 
tantly, it has permitted the definition of new surface 
structures, for which information from any individual 
laboratory working with one reagent would not have 
been sufficient to properly characterize a new antigen. 
In some instances antibodies have been misclassified 
by submitting laboratories, and the workshop analyses 
provide a mechanism for correctly identifying the 
target antigen. This potentially averts many mistakes 
in research laboratories. It is also of value in clinical 
therapeutics, since misclassified antibodies have, on a 
rare occasion, already been in use in clinical protocols. 
Definition of the CD antigens provides a very helpful 
framework for further investigation. This is brought 
about by the direct exchange of information through 
The Human Leukocyte Differentiation Antigen Work- 
shops. 
At the First Workshop, completed in 1982, 137 
antibodies were studied and 15 CD clusters desig- 
nated. At the Fifth Workshop, with participation from 
more than 500 laboratories, culminating with a meeting 
in Boston in November 1993, 1,450 antibodies were 
studied and the list of classified CD antigens was 
extended to 130. 
With the growth of the workshop effort, func- 
tional and biochemical studies have become an in- 
creasingly important part of the work undertaken, and 
often provide important clues to the physiologic role of 
the surface antigens. The use of transfectants and 
recombinant soluble forms of cell surface molecules 
has also accelerated the acquisition of new information 
regarding function and ligands of the various CD 
antigens. Thus, the Human Leukocyte Differentiation 
Antigen Workshops have become an important focus 
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Table 1. Examples of existing CDs with revisions/additions 





































































C3d, receptor, EBV receptor 
FccRII 
IL-2R, Tac antigen 
Ta- 1 
LFA- 1 p 
FcyRII, p40 
CRl,  C3b receptor 
Platelet GPIV, GPIIIb 








VLA-1, a1 integrin chain 
VLA-2, a2 integrin chain 
V L A J ,  03 integrin chain 








p3 integrin chain, GP IIIa, p chain 
E-selectin, ELAM-1 
of the vitronectin receptor 
L-selectin 
P-selectin, CD62, PADGEM, 
Fc yRI 





Ex ressed on T cells, thymocytes, and natural killer (NK) cells; ligands include 
8D58, CD59, and CD48 
Expressed on T cells and thymocytes; associated with the T cell antigen receptor; 
important in signal transduction 
Expressed on major subset of thymocytes and T cells; receptor for class I1 major 
histocompatibility complex (MHC) and human immunodeficiency virus 
Expressed on.Tcells and subset of B cells; reported to bind to CD72 
Distribution similar to CD5; both CD5 and CD6 may be involved in T cell 
activation 
Expressed on T cells and subset of NK cells; class I MHC receptor 
Adhesion molecule expressed on leukocytes; receptor for CD50, CD54, CD102 
Receptor for C3bi and CD54 
Expressed on monocytes, granulocytes, NK cells 
Expressed on monocytes and macrophages; receptor for endotoxin/endotoxin 
binding rotein complex 
Neutrophirligand for the selectin CD62E 
Low-affinity receptor for IgG (Fc yRIIIA, transmembrane form) 
Phosphatidylinositol-linked form of low-affinity Fc IgG receptor 
p subunit of leukocyte integrin family; noncovalently linked to CDl la, b, and c 
Expressed on B cells; involved in B cell activation 
Receptor for C3d and Epstein-Barr virus; expressed on mature B cells 
Low-affinity Fc-IgE receptor; up-regulated by interleukin-4 (IL-4) 
Low-affinity subunit of IL-2 receptor 
Dipeptidyl peptidase IV 
Ligand on T cell for CD80: accessorv uathwav for T cell stimulation _ _  
Common integrin pl subunit 
Low-affinity receptor for IgG 
Aids in binding and phagocytosis of C3b-coated particles 
Endothelial cell receptor for Plasmodium fakiparum-infected red blood cells; 
platelet and monocyte receptor for thrombospondin; member of the tetraspan 
family (includes CD9, CD37, CD53, CD63, and CD81) 
Stimulation by monoclonal antibodies activates B cells; ligand expressed on T cells 
Mediates platelet aggregation; absent on platelets in Glanzmann’s thrombasthenia 
GP IX component of GP Ib/IX complex; von Willebrand factor-dependent 
(Y is 135-kd chain 
p is 25-kd chain 
Homing receptor; role in T cell mitogenesis and cell adhesion; glycosaminoglycan 
Restricted epitope of CD44; specific for exon V9 
Important in cell signaling; is a tyrosine phosphatase; isoforms (CD45RA, 
Cofactor for the factor I-mediated cleavage of C3b, C4b 
Receptor for collagen/laminin 
Receptor for collagen/laminin 
Receptor for epiligrin; weaker binding to collagen, laminin, fibronectin 
a4 1 IS a li and for vascular cell adhesion molecule 1 or CD106; a4p7 is a ligand 
Receptor for fibronectin 
Receptor for laminin 
Ligand for CDI ldCD18 
Integrin expressed on platelets; involved in regulation of hemostasis 
Antibodies have been used for prevention of graft-versus-host disease and 
Intercellular adhesion molecule 1 ; ligand for lym hocyte function-associated 
Decay-accelerating factor; limits complement activation 
Useful for identification of NK cells 
A ligand for CD2 
Inhibits the complement membrane attack complex 
Carbohydrate epitope; expressed on a T cell subset that accumulates in auto- 
immune lesions 
Can associate with CD51 
Adhesion molecule expressed on activated endothelium 
Adhesion molecule widely expressed on leukocytes 
Adhesion molecule expressed on surface of activated platelets and endothelium 
adhesion receptor 
receptor 
CD45R0, CD45RB) identify functional lymphocyte subsets 
{r ;he ajhesion molecule termed MADCAM 
treatment of autoimmune disease 
antigen 1 (LFA-1) (CDlldCD18) and Mac-1 (8Dllb/CD18) 
High-affinity Fc IgG receptor 
Homoloav to TNFa and the CDlO ligand; may be co-activating ligand for T cells - - -  
Transfemn receptor 
Catalvzes deuhosuhorvlation of uurine/uvrimidine ribo/deoxvribo-nucleoside _ _  
mohophosphates . 
Noncovalent association with class I1 MHC: role in intracellular MHC transuort 
and antigen processing 
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Table 2. New CD antigens 















































































TNFR, 55 kd 
TNFR, 75 kd 
IL-IR, type 1 
IL-IR, type 2 
IL-2R 
IL-4R 
I L d R  
IL-7R 
IL-8R 
ILdR,  gpl30SIG 
Signaling molecule associated with B cell surface immunoglobulin 
Signaling molecule associated with B cell surface immunoglobulin 
CD28 counterreceptor 
Member of the tetraspan family; antibody has antiproliferative effects on tumor cells in 
Member of the tetraspan family (includes CD9, CD37, CD53, CD63, CD81) 
Expressed on freshly isolated dendritic cells and on some activated peripheral blood cells 
Expressed on some resting and activated peripheral blood cells; function unknown 
Expressed on plasma cells 
Expressed on macrophages and activated and germinal center B cells 
Receptor for urokinase plasminogen activator 
C5a receptor 
Fc IgA receptor 
Murine homolog expressed on T cells; human antigen present on hematopoietic precursors 
u subunit of a,-macroglobulin receptor 
Expressed on granulocytes and monocytes; function unknown 
Expressed on granulocytes and monocytes; function unknown 
Expressed on granulocytes, monocytes, and natural killer (NK) cells 
Transmits signal for apoptosis 
Expressed primarily on T lymphocytes, late after activation 
Expressed on myeloid cells and activated lymphocytes 
Heterodimeric antigen expressed on most cells and cell lines; increased with activation; 
Pseudoautosomal, multiple epitopes on T lymphocytes; 2 epitopes involved in adhesion 
Antibodies are co-mitogenic for T lymphocytes 
Expressed on myeloid cells; T cell subset 
One of several counterreceptors for LFA-1 (CD1 ldCD18) 
Human mucosal lymphocyte antigen; uE subunit of a E P  
Associates with CD49f 
Transforming growth factor pl  and p3 receptor 
Counterreceptor for Very late activation antigen-4 
Expressed on platelets and in lysosomes; up-regulated to cell surface on activated cells 
Expressed on platelets and in lysosomes; up-regulated to cell surface on activated cells 
glycosylphosphatidyl inositol anchored; expressed on cultured NK cells and selected other 
Expressed on platelets, endothelial cells 
c-fms proto-oncogene product 
Colony-stimulating factor receptor 
Stem cell factor receptor 
Interferon-? receptor 
Type 1 tumor necrosis factor receptor 
Type 2 tumor necrosis factor receptor 
Interleukin-1 (IL-1) receptor, type 1 






Signaling molecule associated with IL-6 receptor and other receptors 
vitro 
and some cell lines 
antibodies bind to the heavy chain 
cell types and lines 
for advancing understanding of the structure and func- 
tion of the CD antigens, as well as classifying them. 
What revisions were made to previously established 
CD clusters? 
Table 1 indicates revisions to previously estab- 
lished CD clusters (CDI-CD78) made at the Fifth 
Workshop, and contains information about the func- 
tion of some of these antigens. When possible, the 
terminology used has been selected to fit well with 
other names for known antigens. For example, the 
selectins have all been clustered within the CD62 
grouping as CD62E, L, and P, respectively, designat- 
ing E-selectin, L-selectin, and P-selectin. Similarly, 
the expanded CD49 grouping sequentially follows the 
previously defined VLA and (Y integrin chain designa- 
tions. One CD antigen, CD67 (not shown in Table l), 
has been left as a vacant cluster, since its structure has 
been found to be most properly grouped in the CD66 
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cluster. Additional information about these antigens 
(1) and their cluster revisions (2) has been published. 
What new CD clusters were established? 
Table 2 lists the new CD antigens clustered at 
the Fifth Workshop. Many of these are molecules of 
known functional importance, and many will be of 
interest to investigators in the rheumatic diseases. 
When possible, workshop committees attempted to 
make CD designations easy to remember. For exam- 
ple, ICAM-2 is CD102. Even more helpful, a variety of 
cytokine receptors for interleukins 1-8 are designated 
CDw121-CDw128. Known receptors for which anti- 
bodies were not available at this workshop, such as the 
interleukin-3 receptor, earned vacant CD slots for 
future assignment. Although specific cell lineage pan- 
els for many of the new CD antigens are indicated in 
Table 2, it is increasingly clear that very few antigens 
are strictly lineage restricted. A more complete de- 
scription of the distribution of these various structures 
is contained in the complete description of the Fifth 
Workshop proceedings (3). Molecular weights of these 
structures have been summarized elsewhere (2). 
What is the future role of the Human Leukocyte 
Differentiation Antigen Workshops? 
The results achieved at the Fifth Workshop and 
at all previous workshops provide strong momentum 
for continuation of the workshop effort. The magni- 
tude of the collaborative efforts involved in these 
workshops provides a model for international scien- 
tific cooperation. However, the workshops will have 
an important role only as long as there are new 
antigens to be identified, and new structural and 
functional information to be learned about the CD 
antigens. That this is the case seems to be beyond 
question. Even at the Fifth Workshop, several very 
interesting surface structures were discussed that have 
been identified so recently that antibodies were not 
available for exchange at the time of organization of 
the workshop. Examples of such structures on T 
lymphocytes include the CD40 ligand and the CTLA4 
antigen. New approaches used during the Fifth Work- 
shop are beginning to extend the scope of CD antigens 
to submembrane and cytoplasmic locations. Endo- 
thelial cell and platelet antigens as well as other 
adhesion ligands are now included within the scope of 
the workshops, representing an expansion beyond the 
surface of leukocytes. It seems likely that other non- 
leukocyte cell types could be added to later work- 
shops. 
It can also be expected that information estab- 
lished through workshop framework will be increas- 
ingly useful in clinical medicine, both for defining cell 
markers useful in monitoring diagnoses or stages of 
disease, and for defining reactivity of antibodies that 
may be used in clinical therapeutics. It will become 
increasingly important to develop new models and 
approaches for understanding the interactions of mul- 
tiple surface receptors in regulating cell functions in a 
coordinated manner. The complexity involved is fur- 
ther accentuated by the growing realization that most 
of the defined surface receptors have multiple ligands, 
both physiologic and microbial. The tasks for future 
workshops, therefore, are more complex and difficult 
than those accomplished to date. Planning for the 
Sixth Workshop is already well under way, with the 
workshop conference scheduled for 1996 in Osaka, 
Japan. 
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